Expression of PD-L1 protein is not the most accurate option for the prediction of response in melanoma (19), as patients with negative PD-L1 in immunohistochemistry can also frequently benefit from anti-PD-1 or anti-PD-L1 therapies (20, 21). This evidence concerns the gene CD274 and melanoma.